Last reviewed · How we verify
ADT
ADT is an androgen deprivation therapy regimen used in prostate cancer treatment to suppress testosterone production and androgen receptor signaling.
ADT is an androgen deprivation therapy regimen used in prostate cancer treatment to suppress testosterone production and androgen receptor signaling. Used for Advanced prostate cancer, Metastatic castration-sensitive prostate cancer.
At a glance
| Generic name | ADT |
|---|---|
| Also known as | Androgen Deprivation Therapy, Goserelin, FDA Approved Antidepressant (ADT), Lupron or Zoladex, Hormone Therapy |
| Sponsor | Canadian Cancer Trials Group |
| Drug class | Androgen deprivation therapy |
| Target | Androgen receptor / testosterone production |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ADT works by reducing circulating testosterone levels through chemical or surgical castration, thereby inhibiting androgen-dependent prostate cancer cell growth. This approach is standard in advanced prostate cancer management, often combined with other agents like androgen receptor antagonists to achieve maximal androgen blockade.
Approved indications
- Advanced prostate cancer
- Metastatic castration-sensitive prostate cancer
Common side effects
- Hot flashes
- Erectile dysfunction
- Fatigue
- Gynecomastia
- Bone loss / osteoporosis
- Metabolic syndrome
Key clinical trials
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments (NA)
- SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer (PHASE2)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy for Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |